Compare BXSL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | BLTE |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.0B |
| IPO Year | 2018 | 2021 |
| Metric | BXSL | BLTE |
|---|---|---|
| Price | $24.77 | $161.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $27.18 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.6M | 153.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 12.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $492.11 |
| P/E Ratio | $164.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.47 | $62.18 |
| 52 Week High | $30.20 | $200.00 |
| Indicator | BXSL | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 51.24 |
| Support Level | $23.08 | $158.32 |
| Resistance Level | $24.69 | $172.02 |
| Average True Range (ATR) | 0.47 | 6.82 |
| MACD | 0.06 | -0.74 |
| Stochastic Oscillator | 78.42 | 27.85 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.